Frequently Asked Questions

What is CBD?

Cannabidiol (CBD) is one of the many naturally occurring cannabinoids found in cannabis plants, accounting for up to 40% of the plant extract 1

Will CBD get me "high"?

Unlike Δ9-tetrahydrocannabinol (THC), CBD is non-psychotropic/psychotomimetic, meaning it won’t get you “high” 1. That being said, some “full spectrum” hemp products contain trace amounts of THC, but not enough to be psychoactive with responsible usage.

Many customers find that CBD products (specifically Full Spectrum products) help them relax, but without any psychoactive effects.

What do people use CBD for?

Because CBD isn’t fully evaluated by the FDA, we can’t legally tell you that there are any benefits to using CBD. That being said, we can tell you to google “Benefits of CBD”, as well as publish links to an abundance of studies suggesting that CBD is far from useless.

How does CBD work?

CBD can be used in a variety of ways. We carry everything from CBD-rich tinctures (CBD oils), vape pens, capsules, smoke-ables… all the way to bath bombs, lotions and sodas infused with CBD.

 

Cannabinoids work with the body’s “endocannabinoid system“. This system consists of two receptors – CB1 and CB2, which bind with cannabinoids to impact various biological processes 2.

Those wanting to delve deeper can find more info here.

Is CBD legal?

State Level – Hemp-derived CBD products containing <0.3% Δ9-THC are legal to possess, use, and sell in the state of Tennessee 3. The products that we carry contain less than 0.3% Δ9-THC, provable by Certificates of Analysis. Our vendors are very transparent with these lab tests, but you’re more than welcome to reach out to us if you’re unable find CoAs on a certain product. Just shoot us an email!

That being said – we do carry hemp flower that closely resembles marijuana. While it is still legal, the close resemblance may raise an eyebrow with law enforcement, so use your best judgement when consuming it!

 

At the time of writing this, CBD is completely illegal in Idaho, South Dakota, West Virginia, Nebraska, Kansas, and Indiana.

 

 

Federal Level – At a Federal level, the DEA has stated that CBD products derived from cannabis (whether industral hemp or marijuana) are a Schedule I controlled substance4. Schedule I substances “has no currently accepted medical use in treatment in the United States”5. However, the FDA has recently approved “Epidiolex”6, a pharmaceutical-grade cannabis-derived CBD oil used to treat childhood epilepsy and seizures.

As of December 20th 2018, Industrial Hemp and Industrial Hemp Derived CBD Products are Federally Legal!

Will I fail a drug test using these products?

Some of the products that we carry are “Full Spectrum” – meaning that they contain all of the cannabinoids from the hemp plant. This includes trace amounts (<0.3%) of Δ9-THC. Customers concerned with drug screens are recommended to stay away from “full spectrum” products, and instead should look at the “isolate” products that we carry.

What's the difference between Isolate and Full Spectrum?

Full Spectrum products contain all of the cannabinoids from the hemp plant, including natural terpenes, CBD, CBDa, CBD, CBC, CBN, Δ9-THC, THCa, and a multitude of other compounds. These cannabinoids work in conjunction with each other to create what is known as the “entourage effect”7, which amplifies its effectiveness in comparison to CBD isolates.

Isolate products are stripped of all cannabinoids except for Cannabidiol, meaning that they are THC-free. The process of isolating CBD from the rest of the plant extract is known as Chromatography. It should be noted that CBD Isolates are generally regarded as being less effective than their full spectrum counterparts.

Sources

  1. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS (December 2012). “Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders”Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences (Review). 367 (1607): 3364-78. doi:10.1098/rstb.2011.0389PMC 3481531PMID 23108553.
  2. Pacher, P., Bátkai, S., & Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological reviews, 58(3), 389-462.
  3. Senator Niceley. (2017, May 11). State of Tennessee – Public Chapter No. 369. Retrieved from https://publications.tnsosfiles.com/acts/110/pub/pc0369.pdf
  4. Federal Register – Vol 81, No. 240. (2016, December 14). Retrieved from https://www.gpo.gov/fdsys/pkg/FR-2016-12-14/pdf/2016-29941.pdf?utm_campaign=subscription%20mailing%20list&utm_source=federalregister.gov&utm_medium=email
  5.  Marshall, Donnie (20 March 2001). “Notice of denial of petition to reschedule marijuana”Federal RegisterDrug Enforcement Administration66 (75): 20038–20076. Retrieved 13 June 2013.
  6.  “FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy”. US Food and Drug Administration. 25 June 2018. Retrieved 25 June 2018.
  7. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R (1998). “An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity”. European Journal of Pharmacology353 (1): 23–31. doi:10.1016/S0014-2999(98)00392-6PMID 9721036.